Form 8-K - Current report:
SEC Accession No. 0001193125-25-201353
Filing Date
2025-09-11
Accepted
2025-09-11 16:30:26
Documents
13
Period of Report
2025-09-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d947118d8k.htm   iXBRL 8-K 29751
2 EX-10.1 d947118dex101.htm EX-10.1 442427
  Complete submission text file 0001193125-25-201353.txt   685618

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cogt-20250905.xsd EX-101.SCH 2855
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cogt-20250905_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cogt-20250905_pre.xml EX-101.PRE 11264
15 EXTRACTED XBRL INSTANCE DOCUMENT d947118d8k_htm.xml XML 3625
Mailing Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451
Business Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451 617-945-5576
Cogent Biosciences, Inc. (Filer) CIK: 0001622229 (see all company filings)

EIN.: 465308248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38443 | Film No.: 251308899
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)